Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Radiation Oncology›Condition·Updated Jun 21, 2026·v1

Cervical Cancer Radiation Management

Radiation management of cervical cancer involves definitive CCRT for locally advanced stages and adjuvant RT/CCRT for early stages with high-risk pathologic features. The integration of MRI-guided brachytherapy and IMRT has significantly improved outcomes and reduced toxicity.

High Evidence182 references·4,149 words·17 min read·v1
Cervical CancerRadiation OncologyBrachytherapyCisplatinIMRT

Quick Reference

RxDrug of choiceWeekly [[Cisplatin]] (40 mg/m²)
AltAlternatives[[Nedaplatin]] (30 mg/m² weekly) or [[Lobaplatin]] (30 mg/m² every 3 weeks for elderly)
⊘AvoidOmission of brachytherapy in curative-intent LACC; SBRT/IMRT boosts as a replacement for brachytherapy
DxTest of choicePelvic [[MRI]] (for local staging and brachytherapy planning)
ScKey scorePeters Criteria (High-risk) and Sedlis Criteria (Intermediate-risk)
→When to referRefer all FIGO IB3+ or node-positive patients to Radiation Oncology for definitive CCRT evaluation
Definitive CCRT with weekly cisplatin and MRI-guided brachytherapy is the curative standard for locally advanced disease, achieving >90% local control when completed within 8 weeks.
Cervical cancer radiation management is a cornerstone of curative therapy, utilizing a combination of external beam radiotherapy (EBRT), concurrent chemotherapy, and brachytherapy. For locally advanced cervical cancer (LACC), defined as FIGO stages IB3 to IVA, the standard of care is definitive concurrent chemoradiotherapy (CCRT) followed by image-guided adaptive brachytherapy (IGABT). This approach leverages the synergistic effects of weekly cisplatin (40 mg/m²) and high-dose radiation to achieve local control rates exceeding 90%. In the postoperative setting, radiation is used adjuvantly based on pathologic risk factors: "high-risk" features (Peters criteria) mandate CCRT, while "intermediate-risk" features (Sedlis criteria) typically warrant RT alone. Modern techniques like IMRT and VMAT have significantly reduced gastrointestinal and genitourinary toxicities, while MRI-guided brachytherapy has shifted the paradigm toward personalized, volume-based dose escalation.

Overview and Recommendations

Background

  • •Locally advanced cervical cancer (LACC) — encompassing FIGO stages IB3 to IVA — represents a high-stakes clinical entity where definitive concurrent chemoradiotherapy (CCRT) serves as the primary curative standard, replacing surgery for these stages. The paradigm shift toward CCRT was solidified by landmark trials showing that adding weekly to radiation reduces the risk of death by 30% to 50%, with a number needed to treat (NNT) of 17 to prevent one death.
  • •Adjuvant radiation therapy is critical for preventing pelvic recurrence in early-stage patients (FIGO IA2–IIA) who undergo radical but harbor pathologic risk factors. These are categorized into high-risk (Peters criteria: positive margins, nodes, or parametria) and intermediate-risk (Sedlis criteria: large tumor size, deep stromal invasion, and lymphovascular space invasion), with the former requiring concurrent chemotherapy to improve 5-year survival by approximately 6%.
  • •Image-guided adaptive brachytherapy (IGABT) has revolutionized local control in LACC, shifting the treatment focus from traditional point-based prescriptions to volume-based MRI optimization. Data from the EMBRACE-I study demonstrate that MRI-guided IGABT achieves 5-year local control rates of 92%, even in bulky tumors, by allowing for precise dose escalation to the high-risk clinical target volume (HR-CTV) while sparing adjacent organs.
  • •The molecular landscape and the role of (HPV) drive the underlying pathophysiology, and emerging biomarkers like circulating tumor DNA (ctDNA) are increasingly used to monitor treatment response. Despite high cure rates in localized disease, untreated or recurrent cases carry a poor prognosis, emphasizing the need for strict adherence to the 8-week total treatment duration window to prevent tumor repopulation.
  • •Technological advancements, specifically the transition from 3D-conformal radiation to and , have halved the incidence of late grade ≥2 gastrointestinal toxicity (from 35% to 19% in the PARCER trial). This improvement in the therapeutic ratio allows for safer delivery of pelvic radiation, particularly in patients requiring extended-field radiation for para-aortic nodal involvement.

Evaluation

  • •Suspect cervical cancer in any patient presenting with post-coital bleeding, intermenstrual spotting, or persistent malodorous vaginal discharge, and perform a thorough speculum and bimanual examination to assess clinical stage.
  • •Order a pelvic as the gold-standard imaging modality for local staging; it is superior to CT for assessing tumor size, parametrial invasion, and vaginal extension, and is mandatory for modern brachytherapy planning.
  • •Obtain a or CT of the chest, abdomen, and pelvis to evaluate for regional lymphadenopathy (pelvic and para-aortic) and distant metastases (FIGO IVB), as nodal involvement significantly alters the radiation field.
  • •Review postoperative pathology for Peters Criteria (positive pelvic lymph nodes, positive surgical margins, or microscopic parametrial involvement), which mandate the initiation of adjuvant concurrent chemoradiotherapy.
  • •Review postoperative pathology for Sedlis Criteria (combination of LVSI, deep stromal invasion, and tumor size ≥4 cm) to determine the need for adjuvant pelvic radiation alone to mitigate locoregional failure.
  • •Perform a simulation CT with the patient in the supine position, utilizing a comfortably full bladder and an empty rectum to displace the small bowel superiorly and minimize gastrointestinal dose.
  • •Define the Clinical Target Volume (CTV) to include the gross tumor (if present), cervix, uterus, parametria, and the upper 2–3 cm of the vagina, along with the internal, external, and common iliac lymph nodes.
  • •Assess renal function (eGFR) and baseline hematologic parameters before initiating concurrent , as renal impairment may necessitate a switch to alternative agents like .
  • •Evaluate the para-aortic lymph node (PALN) status carefully; if PALNs are positive on imaging, the radiation field must be extended superiorly to the level of the renal vessels (Extended-Field IMRT).

Management

  • •Initiate definitive CCRT for FIGO stages IB3–IVA using weekly 40 mg/m² (maximum 70 mg per dose) for 5–6 cycles during the course of external beam radiotherapy.
  • •Deliver EBRT to a total dose of 45.0–50.4 Gy in 1.8–2.0 Gy daily fractions using or to minimize dose to the small bowel, rectum, and bladder.
  • •Administer image-guided adaptive brachytherapy (IGABT) as an indispensable component of curative treatment; it cannot be replaced by EBRT boosts or SBRT without compromising local control and survival.
  • •Aim for a total cumulative dose (EBRT + brachytherapy) of EQD2 ≥85 Gy to the High-Risk Clinical Target Volume (HR-CTV) to maximize the probability of local cure.
  • •Complete the entire course of radiation (EBRT plus brachytherapy) within 56 days (8 weeks), as treatment delays beyond this window result in a ~1% decrease in local control per day.
  • •Adhere to strict OAR (Organs at Risk) constraints to minimize late toxicity: keep the Bladder D2cc <80 Gy, Rectum D2cc <65 Gy, and Sigmoid D2cc <70 Gy (all EQD2).
  • •Utilize interstitial brachytherapy (ISBT) or hybrid applicators for bulky tumors or those with significant parametrial extension that cannot be adequately covered by standard intracavitary applicators.
  • •Prescribe adjuvant CCRT for patients meeting Peters criteria (high-risk) post-hysterectomy to improve overall survival and reduce the risk of pelvic recurrence.
  • •Consider adjuvant RT alone for patients meeting Sedlis criteria (intermediate-risk), although some clinicians may add chemotherapy for "high-intermediate" risk cases despite the lack of definitive trial evidence for this subgroup.
  • •Manage acute radiation-induced diarrhea with or probiotics like Saccharomyces boulardii (250 mg/day) and monitor for hematologic toxicity (neutropenia/lymphopenia) weekly.
  • •Recommend the early and consistent use of vaginal dilators and topical estrogens following the completion of radiation to prevent vaginal stenosis and maintain sexual health.
  • •Provide palliative RT (e.g., 30 Gy in 10 fractions or 8 Gy in a single fraction) for patients with FIGO IVB disease to control hemorrhage, pelvic pain, or symptomatic bone metastases.
  • •Avoid the use of adjuvant systemic chemotherapy after the completion of standard CCRT, as the OUTBACK trial demonstrated no survival benefit with this approach.

Board Review — High Yield

  • •Peters Criteria — Positive nodes, margins, or parametria; mandates adjuvant CCRT.
  • •Sedlis Criteria — LVSI, deep stromal invasion, and large tumor size; warrants adjuvant RT alone.
  • •8-Week Rule — Total treatment duration (EBRT + Brachy) must be <56 days to prevent tumor repopulation.
  • •MRI-Guided Brachytherapy — The gold standard for LACC; delivers EQD2 ≥85 Gy to the HR-CTV.
  • •IMRT vs. 3D-CRT — IMRT significantly reduces late Grade ≥2 GI toxicity (NNT=7).
  • •OUTBACK Trial — Adjuvant chemotherapy after CCRT does not improve overall survival.
  • •Para-aortic Nodes — If positive, the radiation field must be extended to the renal vessels (Extended-Field RT).
  • •Cisplatin Dose — 40 mg/m² weekly, capped at 70 mg per dose.

Deep Dive — Evidence Details

References

  1. [1]

    Koh WJ, Abu-Rustum NR, Bean S et al.. “Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659131 ↗

    L1GUIDELINECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  2. [2]

    Koh WJ, Greer BE, Abu-Rustum NR et al.. “Cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23486458 ↗

    L1GUIDELINECited in: Indications by Stage, Concurrent Chemoradiation
  3. [3]

    Ryu SY, Deng W, Albuquerque K et al.. “Randomized phase III trial of adjuvant radiation versus chemoradiation in intermediate-risk, early-stage cervical cancer following radical hysterectomy and lymphadenectomy: results from NRG Oncology/GOG-263/KGOG 1008.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40947016 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT, Outcomes
  4. [4]

    Sugiyama T, Fujiwara K, Ohashi Y et al.. “Phase III placebo-controlled double-blind randomized trial of radiotherapy for stage IIB-IVA cervical cancer with or without immunomodulator Z-100: a JGOG study.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24569914 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  5. [5]

    Sehouli J, Runnebaum IB, Fotopoulou C et al.. “A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22357252 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  6. [6]

    Cetina L, González-Enciso A, Cantú D et al.. “Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23609186 ↗

    L1RCTCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  7. [7]

    Mayadev J, Vázquez Limón JC, Ramírez Godinez FJ et al.. “Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40500687 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  8. [8]

    Kenter GG, Greggi S, Vergote I et al.. “Randomized Phase III Study Comparing Neoadjuvant Chemotherapy Followed by Surgery Versus Chemoradiation in Stage IB2-IIB Cervical Cancer: EORTC-55994.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37656948 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  9. [9]

    Chopra S, Gupta S, Kannan S et al.. “Late Toxicity After Adjuvant Conventional Radiation Versus Image-Guided Intensity-Modulated Radiotherapy for Cervical Cancer (PARCER): A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34506246 ↗

    L1RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Concurrent Chemoradiation, Adjuvant and Palliative RT, Acute and Late Toxicity
  10. [10]

    da Costa SCS, Bonadio RC, Gabrielli FCG et al.. “Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31449470 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  11. [11]

    Zuliani AC, Esteves SC, Teixeira LC et al.. “Concomitant cisplatin plus radiotherapy and high-dose-rate brachytherapy versus radiotherapy alone for stage IIIB epidermoid cervical cancer: a randomized controlled trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24449243 ↗

    L1RCTCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  12. [12]

    Blohmer JU, Paepke S, Sehouli J et al.. “Randomized phase III trial of sequential adjuvant chemoradiotherapy with or without erythropoietin Alfa in patients with high-risk cervical cancer: results of the NOGGO-AGO intergroup study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21860000 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  13. [13]

    Dueñas-González A, Zarbá JJ, Patel F et al.. “Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21444871 ↗

    L1RCTCited in: Indications by Stage
  14. [14]

    Ryu SY, Nam BH, Kim MH et al.. “A randomized phase III clinical trial of weekly versus tri-weekly cisplatin-based chemoradiotherapy for locally advanced cervical cancer: results of the TACO (GCIG/KGOG 1027/THAI 2012) study.” ESMO open (2026). PMID: 41812622 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  15. [15]

    Yang X, Ren H, Li Z et al.. “A phase III randomized, controlled trial of nedaplatin versus cisplatin concurrent chemoradiotherapy in patients with cervical cancer.” ESMO open (2022). PMID: 35994789 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  16. [16]

    Monk BJ, Toita T, Wu X et al.. “Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2023). PMID: 38039991 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  17. [17]

    Mileshkin LR, Moore KN, Barnes EH et al.. “Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2023). PMID: 37080223 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  18. [18]

    Ruhlmann CH, Christensen TB, Dohn LH et al.. “Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial.” The Lancet. Oncology (2016). PMID: 26952945 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation
  19. [19]

    . “Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19001332 ↗

    L1SR_OBSCited in: Indications by Stage, Adjuvant and Palliative RT, Outcomes
  20. [20]

    Huang H, Feng YL, Wan T et al.. “Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical Cancer: The STARS Phase 3 Randomized Clinical Trial.” JAMA oncology (2021). PMID: 33443541 ↗

    L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT, Outcomes
  21. [21]

    Cho WK, Park W, Kim SW et al.. “Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial.” JAMA oncology (2024). PMID: 38662364 ↗

    L2RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Concurrent Chemoradiation
  22. [22]

    Andrade MO, Al-Alam OCM, Kim HJS et al.. “Induction chemotherapy followed by chemoradiotherapy for locally advanced cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2025). PMID: 40408847 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  23. [23]

    Tzioras S, Pavlidis N, Paraskevaidis E et al.. “Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis.” Cancer treatment reviews (2007). PMID: 17112673 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  24. [24]

    Petrelli F, Riboldi V, Bruschieri L et al.. “First-line treatment of locally advanced cervical carcinoma: An updated systematic review and Bayesian network meta-analysis.” Cancer treatment reviews (2025). PMID: 40086103 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  25. [25]

    Marchetti C, Fagotti A, Tombolini V et al.. “Survival and toxicity in neoadjuvant chemotherapy plus surgery versus definitive chemoradiotherapy for cervical cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 31838220 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  26. [26]

    Rombouts AJM, Hugen N, van Beek JJP et al.. “Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis.” Cancer treatment reviews (2018). PMID: 29957373 ↗

    L1SR_OBSCited in: Indications by Stage, Acute and Late Toxicity
  27. [27]

    Gouy S, Morice P, Narducci F et al.. “Prospective multicenter study evaluating the survival of patients with locally advanced cervical cancer undergoing laparoscopic para-aortic lymphadenectomy before chemoradiotherapy in the era of positron emission tomography imaging.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23857967 ↗

    L2TRIAL_NONRANDOMCited in: Indications by Stage
  28. [28]

    de la Rochefordiere A, Kamal M, Floquet A et al.. “PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25724520 ↗

    L1RCTCited in: Indications by Stage, Outcomes
  29. [29]

    Nakano T, Suzuki Y, Ohno T et al.. “Carbon beam therapy overcomes the radiation resistance of uterine cervical cancer originating from hypoxia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609033 ↗

    L4RCTCited in: Indications by Stage, Outcomes
  30. [30]

    Pötter R, Tanderup K, Schmid MP et al.. “MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study.” The Lancet. Oncology (2021). PMID: 33794207 ↗

    L2TRIAL_NONRANDOMCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation, Outcomes
  31. [31]

    Mayadev JS, Enserro D, Lin YG et al.. “Sequential Ipilimumab After Chemoradiotherapy in Curative-Intent Treatment of Patients With Node-Positive Cervical Cancer.” JAMA oncology (2020). PMID: 31774464 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Concurrent Chemoradiation
  32. [32]

    Höckel M, Wolf B, Schmidt K et al.. “Surgical resection based on ontogenetic cancer field theory for cervical cancer: mature results from a single-centre, prospective, observational, cohort study.” The Lancet. Oncology (2019). PMID: 31383547 ↗

    L2COHORTCited in: Indications by Stage, Adjuvant and Palliative RT, Outcomes
  33. [33]

    Bertolazzi M, Genta ML, Lopes A et al.. “Randomized trial of autologous ovarian graft to preserve ovarian function in young women undergoing pelvic radiotherapy for cervical cancer.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 41759360 ↗

    L1RCTCited in: Indications by Stage
  34. [34]

    Corbeau A, Spampinato S, Charnalia M et al.. “Normal tissue complication probability models for gastrointestinal toxicity after adjuvant (chemo)radiotherapy for cervical cancer in the PARCER trial.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2026). PMID: 41698508 ↗

    L2RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Concurrent Chemoradiation, Acute and Late Toxicity
  35. [35]

    Flint ML, Byrne ME, Friedman CF. “Locally Advanced Cervical Cancer: What is the Preferred Systemic Treatment?” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671446 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  36. [36]

    Xiang M, Kidd EA. “Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31390586 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  37. [37]

    Loiselle C, Koh WJ. “The emerging use of IMRT for treatment of cervical cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147905 ↗

    L5OTHERCited in: Indications by Stage, External Beam Radiotherapy (EBRT)
  38. [38]

    Dyer BA, Zamarin D, Eskandar RN et al.. “Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659133 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  39. [39]

    Papadopoulos KP, Johnson ML, Lockhart AC et al.. “First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796520 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  40. [40]

    Nogueira-Rodrigues A, do Carmo CC, Viegas C et al.. “Phase I trial of erlotinib combined with cisplatin and radiotherapy for patients with locally advanced cervical squamous cell cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18829516 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation, Outcomes
  41. [41]

    Kunos CA, Waggoner S, von Gruenigen V et al.. “Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20145183 ↗

    L4TRIAL_NONRANDOMCited in: Indications by Stage, Concurrent Chemoradiation
  42. [42]

    Tewari KS. “Immune Checkpoint Blockade in PD-L1-Positive Platinum-Refractory Cervical Carcinoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31026210 ↗

    L5CASE_REPORTCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  43. [43]

    . “Prophylactic para-aortic irradiation vs pelvic radiotherapy in pelvic node-positive carcinoma cervix in the setting of concurrent chemoradiation: a phase II open-label multi centric randomized controlled trial (PRO-PARA).” Trials (2026). PMID: 41792812 ↗

    L5RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Brachytherapy, Concurrent Chemoradiation
  44. [44]

    Bonala SR, Raja SA, Subramanian BV et al.. “Randomized comparison of tandem-ring versus tandem-ovoid applicators in volume-based brachytherapy for cervical cancer: Dosimetric analysis and early clinical outcomes.” Brachytherapy (2026). PMID: 41679999 ↗

    L1RCTCited in: Indications by Stage, Brachytherapy
  45. [45]

    Yokoi A, Machida H, Okazawa-Sakai M et al.. “Optimal adjuvant strategy in intermediate-risk cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 42012622 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT
  46. [46]

    Zhou L, Sun C, Diao P et al.. “Efficacy and safety of adding immune checkpoint inhibitors to standard chemotherapy or chemoradiotherapy for advanced or recurrent cervical cancer: a meta-analysis.” Frontiers in immunology (2026). PMID: 41869324 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  47. [47]

    Hathout L, Zhang Y, Lymberis S et al.. “A Systematic Review of Patient-Reported Outcomes on the Impact of Radiation Therapy on Sexual Health in Patients With Gynecologic Cancer.” International journal of radiation oncology, biology, physics (2026). PMID: 41720168 ↗

    L2SR_OBSCited in: Indications by Stage
  48. [48]

    Umemiya M, Kou K, Inayama Y et al.. “Comparison of nedaplatin and cisplatin in concurrent chemoradiotherapy for cervical cancer: a systematic review and meta-analysis.” International journal of clinical oncology (2026). PMID: 41612081 ↗

    L1SR_OBSCited in: Indications by Stage, Concurrent Chemoradiation
  49. [49]

    Chargari C, Martinez A, Michels J et al.. “[French recommendations for clinical practice, Nice/Saint-Paul-de-Vence 2024-2025: Management of localized cervical cancer].” Bulletin du cancer (2026). PMID: 41617621 ↗

    L1GUIDELINECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  50. [50]

    Cho Y, Kim KH, Yoon HI et al.. “Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502717 ↗

    L3OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  51. [51]

    Schmid MP, Lindegaard JC, Mahantshetty U et al.. “Risk Factors for Local Failure Following Chemoradiation and Magnetic Resonance Image-Guided Brachytherapy in Locally Advanced Cervical Cancer: Results From the EMBRACE-I Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36599120 ↗

    L2OTHERCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  52. [52]

    Dryden-Peterson S, Bvochora-Nsingo M, Suneja G et al.. “HIV Infection and Survival Among Women With Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27573661 ↗

    L2OTHERCited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation
  53. [53]

    Rose PG, Java J, Whitney CW et al.. “Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732170 ↗

    L3OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  54. [54]

    Wenzel HHB, Olthof EP, Bekkers RLM et al.. “Primary or adjuvant chemoradiotherapy for cervical cancer with intraoperative lymph node metastasis - A review.” Cancer treatment reviews (2022). PMID: 34773774 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  55. [55]

    Wieringa HW, van der Zee AG, de Vries EG et al.. “Breaking the DNA damage response to improve cervical cancer treatment.” Cancer treatment reviews (2016). PMID: 26643553 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Concurrent Chemoradiation, Outcomes
  56. [56]

    Cabel L, Bonneau C, Bernard-Tessier A et al.. “HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer.” ESMO open (2021). PMID: 34022731 ↗

    L3OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  57. [57]

    Westerveld H, Nesvacil N, Fokdal L et al.. “Definitive radiotherapy with image-guided adaptive brachytherapy for primary vaginal cancer.” The Lancet. Oncology (2020). PMID: 32135119 ↗

    L5REVIEW_NARRATIVECited in: Indications by Stage, Brachytherapy, Concurrent Chemoradiation, Outcomes
  58. [58]

    Elbanna M, Pynda Y, Kalinchuk O et al.. “Radiotherapy resources in Latin America and the Caribbean: a review of current and projected needs based on International Atomic Energy Agency data.” The Lancet. Oncology (2023). PMID: 37657478 ↗

    L2REVIEW_NARRATIVECited in: Indications by Stage, Brachytherapy
  59. [59]

    Hajeer A, Salem A, Akash M et al.. “Assessing the global demand and supply of brachytherapy resources: a population-based observational study.” The Lancet. Oncology (2026). PMID: 41785895 ↗

    L2OTHERCited in: Indications by Stage, Brachytherapy
  60. [60]

    Elmore SNC, Polo A, Bourque JM et al.. “Radiotherapy resources in Africa: an International Atomic Energy Agency update and analysis of projected needs.” The Lancet. Oncology (2021). PMID: 34478675 ↗

    L2OTHERCited in: Indications by Stage
  61. [61]

    Rodin D, Burger EA, Atun R et al.. “Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact.” The Lancet. Oncology (2019). PMID: 31151906 ↗

    L2OTHERCited in: Indications by Stage
  62. [62]

    Scott JG, Berglund A, Schell MJ et al.. “A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study.” The Lancet. Oncology (2017). PMID: 27993569 ↗

    L3OTHERCited in: Indications by Stage
  63. [63]

    Höckel M, Hentschel B, Horn LC. “Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.” The Lancet. Oncology (2014). PMID: 24656439 ↗

    L2OTHERCited in: Indications by Stage, Adjuvant and Palliative RT
  64. [64]

    Du Q, Liu Q, Zhou Y et al.. “Primary prophylaxis with pegylated G-CSF is associated with improved treatment completion and progression-free survival in locally advanced cervical cancer undergoing concurrent chemoradiotherapy: a retrospective cohort study.” Future oncology (London, England) (2026). PMID: 41930746 ↗

    L3COHORTCited in: Indications by Stage
  65. [65]

    Malikova H, Graffneter K, Kremenova K et al.. “Pretreatment computed tomography L1 attenuation values: Easy reaching predicting factor for radiation-related bone insufficiency fractures in females treated for advanced cervical cancer (prospective study).” Women's health (London, England) (2026). PMID: 41746818 ↗

    L2COHORTCited in: Indications by Stage, Acute and Late Toxicity
  66. [66]

    Agustí N, Viveros-Carreño D, Wu CF et al.. “Adjuvant Chemoradiotherapy vs Radiotherapy Alone for Patients With Intermediate-Risk Cervical Cancer.” JAMA oncology (2025). PMID: 40079948 ↗

    L3OTHERCited in: Indications by Stage, Concurrent Chemoradiation, Adjuvant and Palliative RT
  67. [67]

    Wang Y, Farmer M, Izaguirre EW et al.. “Association of Definitive Pelvic Radiation Therapy With Survival Among Patients With Newly Diagnosed Metastatic Cervical Cancer.” JAMA oncology (2018). PMID: 30054609 ↗

    L3OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  68. [68]

    Colbert LE, El Alam MB, Wang R et al.. “Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring.” Cancer cell (2023). PMID: 37863066 ↗

    L5OTHERCited in: Indications by Stage
  69. [69]

    Lukovic J, Pintilie M, Han K et al.. “An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38180733 ↗

    L3OTHERCited in: Indications by Stage
  70. [70]

    Mondini M, Deutsch E. “(Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33986023 ↗

    L5OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  71. [71]

    Seo A, Xiao W, Gjyshi O et al.. “Human Papilloma Virus Circulating Cell-Free DNA Kinetics in Patients with Cervical Cancer Undergoing Definitive Chemoradiation.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39680029 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  72. [72]

    Chaudary N, Pintilie M, Jelveh S et al.. “Plerixafor Improves Primary Tumor Response and Reduces Metastases in Cervical Cancer Treated with Radio-Chemotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 27697997 ↗

    L5OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  73. [73]

    Chen J, Chen C, Zhan Y et al.. “Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33766815 ↗

    L2OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  74. [74]

    Ju XZ, Yang JM, Zhou XY et al.. “EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18223224 ↗

    L3OTHERCited in: Indications by Stage, Brachytherapy
  75. [75]

    Lee J, Chang CL, Lin JB et al.. “Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29959140 ↗

    L3OTHERCited in: Indications by Stage, Concurrent Chemoradiation
  76. [76]

    Dankulchai P, Prasartseree T, Sittiwong W et al.. “Early Results of Hypofractionated Chemoradiation in Cervical Cancer with 44 Gy/ 20 F vs 45 Gy/ 25 F: A Phase II, Open-Label, Randomised Controlled Trial (HYPOCx-iRex Trial).” Clinical oncology (Royal College of Radiologists (Great Britain)) (2025). PMID: 40897075 ↗

    L1RCTCited in: External Beam Radiotherapy (EBRT)
  77. [77]

    Cho WK, Park W, Lee JH et al.. “Postoperative conventional versus hypofractionated intensity-modulated radiation therapy with concurrent chemotherapy in cervical cancer: a prospective multicenter randomized phase III trial (POHIM_P3 trial).” Journal of gynecologic oncology (2026). PMID: 40676909 ↗

    L5TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT)
  78. [78]

    Zeng Z, Chen Y, Qiu J et al.. “Moderately hypofractionated online adaptive radiotherapy (SWIFT-1) in cervical cancer patients: study protocol for a multi-centered, open-label, two-arm, phase III, randomized controlled study.” Radiation oncology (London, England) (2025). PMID: 40671096 ↗

    L5TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT)
  79. [79]

    Cho WK, Park W, Kim SW et al.. “Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).” Gynecologic oncology (2025). PMID: 40449127 ↗

    L2TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT), Adjuvant and Palliative RT
  80. [80]

    You J, Wu D, Tie J et al.. “Phase I clinical trial of lobaplatin combined with image-guided volume-modulated arc radiation therapy in locally advanced cervical cancer.” BMC cancer (2026). PMID: 42168915 ↗

    L4TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT), Brachytherapy
  81. [81]

    Lebret D, Lafond C, Leseur J et al.. “Prospective multi-institutional study of library-based adaptive radiotherapy for cervical cancer: Evaluation of plan-of-the-day selection and population analysis.” Journal of applied clinical medical physics (2025). PMID: 41253687 ↗

    L2TRIAL_NONRANDOMCited in: External Beam Radiotherapy (EBRT)
  82. [82]

    Ma J, Wang G, Wang W et al.. “Extended-field intensity-modulated radiation therapy and high-dose-rate brachytherapy with concurrent chemotherapy for cervical cancer with positive para-aortic or common iliac lymph nodes: a multicenter prospective cohort study.” Journal of gynecologic oncology (2026). PMID: 42210768 ↗

    L2COHORTCited in: External Beam Radiotherapy (EBRT), Brachytherapy, Concurrent Chemoradiation
  83. [83]

    Riggenbach E, Mose L, Imboden S et al.. “Intensified radiochemotherapy with cisplatin and gemcitabine for cervical cancer in the modern era: a retrospective cohort study.” Journal of gynecologic oncology (2026). PMID: 41413788 ↗

    L3COHORTCited in: External Beam Radiotherapy (EBRT), Brachytherapy
  84. [84]

    Manea E, Anghel B, Stanescu AD et al.. “Adaptive Target Volume and Dosimetry in Image-Guided Radiotherapy for Cervical Cancer.” Journal of clinical medicine (2025). PMID: 40429413 ↗

    L4CASE_REPORTCited in: External Beam Radiotherapy (EBRT)
  85. [85]

    Xu M, Kang K, Zhao M et al.. “Optimizing ovarian dose sparing for young cervical cancer patients after oophoropexy: a dosimetric and radiobiological comparison of three radiotherapy techniques (IMPT, TOMO, and VMAT).” Radiation oncology (London, England) (2026). PMID: 42243980 ↗

    L4OTHERCited in: External Beam Radiotherapy (EBRT)
  86. [86]

    Mayadev J, Deng W, Kim H et al.. “Radiation Quality and Workflow in NRG GY017: Anti PD-L1 (Atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer.” International journal of radiation oncology, biology, physics (2026). PMID: 42184868 ↗

    L1OTHERCited in: External Beam Radiotherapy (EBRT)
  87. [87]

    Lee SS, Weil CR, Boyd L et al.. “Trends in Intensity Modulated Radiation Therapy Utilization for Definitive Treatment of Intact Cervical Cancer, 2004-2019.” Advances in radiation oncology (2026). PMID: 42183318 ↗

    L2OTHERCited in: External Beam Radiotherapy (EBRT)
  88. [88]

    Shinde P, Ak A, Agarwal P et al.. “Spatially fractionated radiotherapy using straight and bending virtual rods as an alternative for cervical cancer brachytherapy-results from preclinical in-silico dose comparison and quality assurance.” The British journal of radiology (2026). PMID: 42179164 ↗

    L4OTHERCited in: External Beam Radiotherapy (EBRT)
  89. [89]

    Hu L, Li J, Du Y et al.. “Lobaplatin versus cisplatin in concurrent chemoradiotherapy for elderly cervical cancer: randomized controlled phase II study.” Journal of gynecologic oncology (2026). PMID: 41381401 ↗

    L1RCTCited in: Brachytherapy, Concurrent Chemoradiation
  90. [90]

    Ebner C, Purtscheller R, Feroz B et al.. “Biopsy-proven residual cervical cancer at the end of combined chemoradiation predicts poor outcome-Retrospective single-center cohort study.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 41423908 ↗

    L3COHORTCited in: Brachytherapy
  91. [91]

    Zhou J, Cai J, Li X et al.. “Pelvic radiotherapy combined with immunotherapy and chemotherapy for stage IVB cervical cancer: a retrospective study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41411697 ↗

    L3COHORTCited in: Brachytherapy
  92. [92]

    Sun Y, Chen Y, Zeng Z et al.. “Metal artifact reduction in spectral computed tomography for intracavity brachytherapy in cervical cancer patients: a prospective study.” Radiation oncology (London, England) (2025). PMID: 41327225 ↗

    L4COHORTCited in: Brachytherapy
  93. [93]

    Cvancarova M, Samuelsen SO, Magelssen H et al.. “Reproduction rates after cancer treatment: experience from the Norwegian radium hospital.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19075285 ↗

    L2OTHERCited in: Brachytherapy
  94. [94]

    Nakashima T, Matsumoto K, Yoshitake T et al.. “Impact of high-dose pelvic radiotherapy combined with chemotherapy on local control, symptom relief, and safety in patients with stage IVB cervical cancer (FIGO 2018): a two-center retrospective study.” Japanese journal of radiology (2026). PMID: 41441948 ↗

    L3COHORTCited in: Brachytherapy, Acute and Late Toxicity
  95. [95]

    Liu R, Fan Z, Ma H et al.. “Best evidence summary on sexual health management for patients undergoing intracavitary brachytherapy for gynecological neoplasms.” Frontiers in oncology (2026). PMID: 41695375 ↗

    L1SR_OBSCited in: Brachytherapy
  96. [96]

    Straathof R, Pool LI, van Vliet-Pérez SM et al.. “Clinical factors affecting the therapeutic dose window in cervical cancer brachytherapy: A systematic review and meta-regression.” Brachytherapy (2026). PMID: 41444098 ↗

    L1SR_OBSCited in: Brachytherapy
  97. [97]

    Sargazi V, Naseri S, Gholamhosseinian H et al.. “Applicator reconstruction in cervical cancer brachytherapy: A systematic review of current methods, challenges, and AI-driven future directions.” Brachytherapy (2026). PMID: 41344965 ↗

    L1SR_OBSCited in: Brachytherapy
  98. [98]

    Noordhuis MG, Eijsink JJ, Ten Hoor KA et al.. “Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19920104 ↗

    L3OTHERCited in: Brachytherapy
  99. [99]

    Ilia G, Thomopoulos A, Chronas D. “Preserved Menstruation After Chemoradiotherapy in Stage IIIC1 Cervical Cancer: A Unique Case.” Journal of clinical medicine (2026). PMID: 41753237 ↗

    L4CASE_REPORTCited in: Brachytherapy
  100. [100]

    Lissoni AA, Colombo N, Pellegrino A et al.. “A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the Snap-02 Italian Collaborative Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19181826 ↗

    L1RCTCited in: Concurrent Chemoradiation
  101. [101]

    Gupta S, Maheshwari A, Parab P et al.. “Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29432076 ↗

    L1RCTCited in: Concurrent Chemoradiation, Outcomes
  102. [102]

    Kitagawa R, Katsumata N, Shibata T et al.. “Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25732161 ↗

    L1RCTCited in: Concurrent Chemoradiation, Outcomes
  103. [103]

    Symonds RP, Gourley C, Davidson S et al.. “Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.” The Lancet. Oncology (2015). PMID: 26474517 ↗

    L1RCTCited in: Concurrent Chemoradiation, Outcomes
  104. [104]

    Tewari KS, Sill MW, Long HJ et al.. “Improved survival with bevacizumab in advanced cervical cancer.” The New England journal of medicine (2014). PMID: 24552320 ↗

    L1RCTCited in: Concurrent Chemoradiation
  105. [105]

    Penson RT, Huang HQ, Wenzel LB et al.. “Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).” The Lancet. Oncology (2015). PMID: 25638326 ↗

    L1TRIAL_NONRANDOMCited in: Concurrent Chemoradiation, Outcomes
  106. [106]

    Tewari KS, Colombo N, Monk BJ et al.. “Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer: Subgroup Analyses From the KEYNOTE-826 Randomized Clinical Trial.” JAMA oncology (2024). PMID: 38095881 ↗

    L1RCTCited in: Concurrent Chemoradiation
  107. [107]

    Thaker PH, Salani R, Brady WE et al.. “A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27998970 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemoradiation, Outcomes
  108. [108]

    Tewari KS, Sill MW, Monk BJ et al.. “Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26672085 ↗

    L2RCTCited in: Concurrent Chemoradiation, Outcomes
  109. [109]

    Li K, Chen J, Hu Y et al.. “Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial.” The Lancet. Oncology (2024). PMID: 38048802 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemoradiation
  110. [110]

    Gray HJ. “Primary management of early stage cervical cancer (IA1-IB) and appropriate selection of adjuvant therapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18267058 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation, Adjuvant and Palliative RT
  111. [111]

    Oaknin A, Ghamande SA, Kasamatsu Y et al.. “Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38165683 ↗

    L4TRIAL_NONRANDOMCited in: Concurrent Chemoradiation
  112. [112]

    Kidd EA, Grigsby PW. “Intratumoral metabolic heterogeneity of cervical cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18698042 ↗

    L2TRIAL_NONRANDOMCited in: Concurrent Chemoradiation, Outcomes
  113. [113]

    Piya IJ, Riya IJ, Sharma V. “Efficacy and safety of immune checkpoint inhibitors with chemoradiotherapy/chemotherapy in locally advanced cervical cancer patients: a systematic review and single-arm meta-analysis.” Journal of gynecologic oncology (2026). PMID: 41267534 ↗

    L1SR_OBSCited in: Concurrent Chemoradiation, Outcomes
  114. [114]

    Long HJ. “Management of metastatic cervical cancer: review of the literature.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17617528 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation
  115. [115]

    Wei S, Li X, Liu Z et al.. “Nimotuzumab plus concurrent chemoradiotherapy sequential maintenance treatment for locally advanced cervical squamous cell carcinoma (NOTABLE-306): a multicenter, prospective, randomized, double-blind, placebo-controlled trial.” Journal of gynecologic oncology (2026). PMID: 41514314 ↗

    L5TRIAL_NONRANDOMCited in: Concurrent Chemoradiation
  116. [116]

    Pectasides D, Kamposioras K, Papaxoinis G et al.. “Chemotherapy for recurrent cervical cancer.” Cancer treatment reviews (2008). PMID: 18657909 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation, Outcomes
  117. [117]

    Gennigens C, Jerusalem G, Lapaille L et al.. “Recurrent or primary metastatic cervical cancer: current and future treatments.” ESMO open (2022). PMID: 36108558 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation
  118. [118]

    Gouy S, Morice P, Narducci F et al.. “Nodal-staging surgery for locally advanced cervical cancer in the era of PET.” The Lancet. Oncology (2012). PMID: 22554549 ↗

    L5REVIEW_NARRATIVECited in: Concurrent Chemoradiation
  119. [119]

    Zhang Y, Meng Y, Shi H et al.. “Prevalence and influencing factors of depressive and anxiety symptoms in cervical cancer patients during the peri-chemoradiotherapy period: A systematic review meta-analysis.” Medicine (2026). PMID: 41559991 ↗

    L2SR_OBSCited in: Concurrent Chemoradiation
  120. [120]

    Zhao X, Singhal A, Park S et al.. “Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress.” Cancer discovery (2024). PMID: 38236062 ↗

    L5OTHERCited in: Concurrent Chemoradiation
  121. [121]

    Ishida S, McCormick F, Smith-McCune K et al.. “Enhancing tumor-specific uptake of the anticancer drug cisplatin with a copper chelator.” Cancer cell (2010). PMID: 20541702 ↗

    L5OTHERCited in: Concurrent Chemoradiation, Outcomes
  122. [122]

    Sannigrahi MK, Sharma R, Singh V et al.. “Role of Host miRNA Hsa-miR-139-3p in HPV-16-Induced Carcinomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28143871 ↗

    L5OTHERCited in: Concurrent Chemoradiation
  123. [123]

    Reid E, Suneja G, Ambinder RF et al.. “Cancer in People Living With HIV, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30099375 ↗

    L1GUIDELINECited in: Adjuvant and Palliative RT
  124. [124]

    Chargari C, Ducassou A, Laville A et al.. “Radiotherapy and brachytherapy for cervical cancer: Recommendations of the Société française de radiothérapie oncologique.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 41086563 ↗

    L1GUIDELINECited in: Adjuvant and Palliative RT
  125. [125]

    Park JY, Kim DY, Kim JH et al.. “Management of occult invasive cervical cancer found after simple hysterectomy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19858083 ↗

    L3OTHERCited in: Adjuvant and Palliative RT, Outcomes
  126. [126]

    Park JY, Kim DY, Kim JH et al.. “Outcomes after radical hysterectomy according to tumor size divided by 2-cm interval in patients with early cervical cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 20595451 ↗

    L4OTHERCited in: Adjuvant and Palliative RT
  127. [127]

    Bai F, Wu G, Qu X et al.. “Optimal adjuvant radiotherapy strategy for cervical cancer: a multi-center database cohort study.” International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2026). PMID: 41308331 ↗

    L2COHORTCited in: Adjuvant and Palliative RT
  128. [128]

    Chase DM, Huang HQ, Deng W et al.. “Patient-reported outcomes of a randomized phase III clinical trial of adjuvant radiation versus chemoradiation in intermediate risk, stage I/IIA cervical cancer patients treated with initial radical hysterectomy and pelvic lymphadenectomy (NRG/GOG-0263).” Gynecologic oncology (2025). PMID: 41056581 ↗

    L1RCTCited in: Adjuvant and Palliative RT
  129. [129]

    Hardie AN, Wenzel HHB, Schnack TH et al.. “Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.” European journal of cancer (Oxford, England : 1990) (2025). PMID: 40795525 ↗

    L2COHORTCited in: Adjuvant and Palliative RT
  130. [130]

    Kidd EA, Siegel BA, Dehdashti F et al.. “Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20308664 ↗

    L2OTHERCited in: Adjuvant and Palliative RT
  131. [131]

    Russo AL, Depauw N, Horick NK et al.. “Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix.” International journal of radiation oncology, biology, physics (2025). PMID: 40089072 ↗

    L2TRIAL_NONRANDOMCited in: Adjuvant and Palliative RT
  132. [132]

    Okuma K, Murakami N, Inaba K et al.. “Gel spacer-assisted salvage brachytherapy for pelvic recurrence after definitive chemoradiotherapy in cervical cancer: A single-institution retrospective study.” Brachytherapy (2025). PMID: 40769797 ↗

    L4COHORTCited in: Adjuvant and Palliative RT
  133. [133]

    Ooko F, Mothiba T, Van Bogaert P et al.. “Access to palliative care in patients with advanced cancer of the uterine cervix in the low- and middle-income countries: a systematic review.” BMC palliative care (2023). PMID: 37726748 ↗

    L2SR_OBSCited in: Adjuvant and Palliative RT
  134. [134]

    Sarfati D, Dyer R, Sam FA et al.. “Cancer control in the Pacific: big challenges facing small island states.” The Lancet. Oncology (2019). PMID: 31395476 ↗

    L5REVIEW_NARRATIVECited in: Adjuvant and Palliative RT
  135. [135]

    Weidhaas JB, Li SX, Winter K et al.. “Changes in gene expression predicting local control in cervical cancer: results from Radiation Therapy Oncology Group 0128.” Clinical cancer research : an official journal of the American Association for Cancer Research (2009). PMID: 19509178 ↗

    L2OTHERCited in: Adjuvant and Palliative RT
  136. [136]

    Rose PG, Ali S, Watkins E et al.. “Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17502627 ↗

    L1RCTCited in: Acute and Late Toxicity
  137. [137]

    Monk BJ, Sill MW, Burger RA et al.. “Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19139430 ↗

    L2TRIAL_NONRANDOMCited in: Acute and Late Toxicity
  138. [138]

    Chen G, Wang M, Lin E et al.. “Herbal medicines for radiation vaginitis: A systematic review and meta-analysis.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2025). PMID: 41086674 ↗

    L1SR_OBSCited in: Acute and Late Toxicity
  139. [139]

    Takekuma M, Nishio S, Yamaguchi S et al.. “Atezolizumab, bevacizumab, and platinum chemotherapy in cervical cancer: results of Japanese population from BEATcc.” Journal of gynecologic oncology (2025). PMID: 40968753 ↗

    L1RCTCited in: Acute and Late Toxicity
  140. [140]

    Wang Y, Zhang X, Wang F et al.. “Dosimetric and Clinical Effects of Polyethylene Glycol Gel in Radical Concurrent Chemoradiation Therapy for Cervical Cancer: A Phase 3 Prospective Multicenter Randomized Controlled Trial.” International journal of radiation oncology, biology, physics (2026). PMID: 40876576 ↗

    L1RCTCited in: Acute and Late Toxicity
  141. [141]

    Muangwong P, Tharavichitkul E, Thiennimitr P et al.. “Impact of Saccharomyces boulardii on acute gastrointestinal toxicities in patients undergoing pelvic radiotherapy for gynecologic cancers: a randomized controlled trial.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 40526282 ↗

    L1RCTCited in: Acute and Late Toxicity
  142. [142]

    Chikazawa K, Imai K, Ko H et al.. “Adjuvant chemotherapy after radical hysterectomy yields comparable outcomes to chemoradiation for stage IB2-IIB and IIIC1-2 cervical cancer: a single-center retrospective study.” Journal of gynecologic oncology (2025). PMID: 40114548 ↗

    L3COHORTCited in: Acute and Late Toxicity
  143. [143]

    Hwang JH, Kim B. “Postoperative Urinary Complications in Minimally Invasive Versus Abdominal Radical Hysterectomy: A Meta-Analysis With a Focus on Ureterovaginal Fistula.” Journal of minimally invasive gynecology (2025). PMID: 39710105 ↗

    L2SR_OBSCited in: Acute and Late Toxicity
  144. [144]

    Saini SK, Srivastava S, Goel A et al.. “Outcomes of Stage IVA Cervical Cancer Treated with Radiation Therapy: A Systematic Review and Meta-Analysis.” International journal of radiation oncology, biology, physics (2026). PMID: 42034194 ↗

    L2SR_OBSCited in: Acute and Late Toxicity
  145. [145]

    Pham TN, Coupey J, Valable S et al.. “Tumor Site-Specific Radiation-Induced Lymphocyte Depletion Models After Fractionated Radiotherapy: Considerations of Model Structure From an Aggregate Data Meta-Analysis.” JCO clinical cancer informatics (2025). PMID: 41118606 ↗

    L2SR_OBSCited in: Acute and Late Toxicity
  146. [146]

    Kelley J, Yao M, Chau D et al.. “Maintenance bevacizumab following chemotherapy is associated with improved survival in patients with advanced and recurrent cervical cancer in a single-institution retrospective study.” Gynecologic oncology reports (2025). PMID: 40092738 ↗

    L3COHORTCited in: Acute and Late Toxicity
  147. [147]

    Lorusso D, Colombo N, Dubot C et al.. “Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 39393777 ↗

    L1RCTCited in: Outcomes
  148. [148]

    Nam JH, Park JY, Kim DY et al.. “Laparoscopic versus open radical hysterectomy in early-stage cervical cancer: long-term survival outcomes in a matched cohort study.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 21841155 ↗

    L3COHORTCited in: Outcomes
  149. [149]

    Ramirez PT, Robledo KP, Frumovitz M et al.. “LACC Trial: Final Analysis on Overall Survival Comparing Open Versus Minimally Invasive Radical Hysterectomy for Early-Stage Cervical Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38810208 ↗

    L1RCTCited in: Outcomes
  150. [150]

    Wenzel L, Osann K, Hsieh S et al.. “Psychosocial telephone counseling for survivors of cervical cancer: results of a randomized biobehavioral trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25713429 ↗

    L1RCTCited in: Outcomes
  151. [151]

    Monk BJ, Mas Lopez L, Zarba JJ et al.. “Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20606083 ↗

    L1RCTCited in: Outcomes
  152. [152]

    Lorusso D, Ferrandina G, Pignata S et al.. “Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 19605508 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  153. [153]

    Zagouri F, Korakiti AM, Zakopoulou R et al.. “Taxanes during pregnancy in cervical cancer: A systematic review and pooled analysis.” Cancer treatment reviews (2019). PMID: 31442939 ↗

    L2SR_OBSCited in: Outcomes
  154. [154]

    Bentivegna E, Gouy S, Maulard A et al.. “Oncological outcomes after fertility-sparing surgery for cervical cancer: a systematic review.” The Lancet. Oncology (2016). PMID: 27299280 ↗

    L2SR_OBSCited in: Outcomes
  155. [155]

    Oaknin A, Moore K, Meyer T et al.. “Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.” The Lancet. Oncology (2024). PMID: 38608691 ↗

    L1RCTCited in: Outcomes
  156. [156]

    McCredie MR, Sharples KJ, Paul C et al.. “Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study.” The Lancet. Oncology (2008). PMID: 18407790 ↗

    L3COHORTCited in: Outcomes
  157. [157]

    Vergote I, González-Martín A, Fujiwara K et al.. “Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.” The New England journal of medicine (2024). PMID: 38959480 ↗

    L1RCTCited in: Outcomes
  158. [158]

    Ramirez PT, Frumovitz M, Pareja R et al.. “Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer.” The New England journal of medicine (2018). PMID: 30380365 ↗

    L1RCTCited in: Outcomes
  159. [159]

    Colombo N, Dubot C, Lorusso D et al.. “Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer.” The New England journal of medicine (2021). PMID: 34534429 ↗

    L1RCTCited in: Outcomes
  160. [160]

    . “Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.” The New England journal of medicine (2007). PMID: 17494925 ↗

    L1RCTCited in: Outcomes
  161. [161]

    Frenel JS, Le Tourneau C, O'Neil B et al.. “Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29095678 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  162. [162]

    Naumann RW, Hollebecque A, Meyer T et al.. “Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31487218 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  163. [163]

    Lan C, Shen J, Wang Y et al.. “Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 33052760 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  164. [164]

    Youn JW, Hur SY, Woo JW et al.. “Pembrolizumab plus GX-188E therapeutic DNA vaccine in patients with HPV-16-positive or HPV-18-positive advanced cervical cancer: interim results of a single-arm, phase 2 trial.” The Lancet. Oncology (2020). PMID: 33271094 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  165. [165]

    Frumovitz M, Obermair A, Coleman RL et al.. “Quality of life in patients with cervical cancer after open versus minimally invasive radical hysterectomy (LACC): a secondary outcome of a multicentre, randomised, open-label, phase 3, non-inferiority trial.” The Lancet. Oncology (2020). PMID: 32502445 ↗

    L1TRIAL_NONRANDOMCited in: Outcomes
  166. [166]

    Abu-Rustum NR, Sonoda Y. “Fertility-sparing surgery in early-stage cervical cancer: indications and applications.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 21147906 ↗

    L4OTHERCited in: Outcomes
  167. [167]

    Pennington KP, Urban RR, Gray HJ. “Revisiting Minimally Invasive Surgery in the Management of Early-Stage Cervical Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30659132 ↗

    L5REVIEW_NARRATIVECited in: Outcomes
  168. [168]

    Hong DS, Concin N, Vergote I et al.. “Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 31796521 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  169. [169]

    Stevanović S, Helman SR, Wunderlich JR et al.. “A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30518633 ↗

    L4TRIAL_NONRANDOMCited in: Outcomes
  170. [170]

    Mi X, Lin T, Zhu X et al.. “Efficacy and safety of cadonilimab for malignant solid tumor treatment: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42292353 ↗

    L1SR_OBSCited in: Outcomes
  171. [171]

    Zhang D, Meng Y, Dong X et al.. “Efficacy and safety of immune checkpoint inhibitors combined with antiangiogenic agents in advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2026). PMID: 42253994 ↗

    L1SR_OBSCited in: Outcomes
  172. [172]

    Wang X, Zhang Y, Wang C et al.. “Efficacy and safety of first-line therapies for persistent, recurrent, or metastatic cervical cancer: a systematic review and exploratory network meta-analysis of immunotherapy.” Frontiers in immunology (2026). PMID: 42079658 ↗

    L1SR_OBSCited in: Outcomes
  173. [173]

    Panczel I, Herold M, Borbenyi E et al.. “Survival Difference in Advanced-Stage Cervical and Ovarian Cancer Patients Treated with Concomitant Modulated Electro-Hyperthermia in Comparison to Classic Treatment Modalities: Results of a Pilot Study and Meta-Analysis.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892820 ↗

    L2SR_OBSCited in: Outcomes
  174. [174]

    Zhou J, Ye W, Ranarisoa SN et al.. “Comparison of drug regimens for recurrent or metastatic cervical cancer: a systematic review and network meta-analysis.” Frontiers in immunology (2026). PMID: 41822503 ↗

    L1SR_OBSCited in: Outcomes
  175. [175]

    Zhuang Q, Liu Y. “Efficacy and safety of Cadonilimab in the treatment of recurrent/metastatic and advanced cervical cancer: a systematic review and meta-analysis.” Frontiers in immunology (2025). PMID: 41601625 ↗

    L2SR_OBSCited in: Outcomes
  176. [176]

    Shi A, Yerebake M, Du Z et al.. “Acupuncture as Adjunctive Therapy for Cervical Cancer Pain: A Systematic Review and Meta-Analysis.” Journal of pain and symptom management (2026). PMID: 41482014 ↗

    L1SR_OBSCited in: Outcomes
  177. [177]

    Verleye L, Vergote I, Reed N et al.. “Quality assurance for radical hysterectomy for cervical cancer: the view of the European Organization for Research and Treatment of Cancer--Gynecological Cancer Group (EORTC-GCG).” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19556323 ↗

    L5REVIEW_NARRATIVECited in: Outcomes
  178. [178]

    Kim JH, Hwang WY, Choi CH et al.. “Oncologic outcomes and the impact of minimally invasive surgery in early-stage cervical cancer patients undergoing radical trachelectomy: A retrospective multicenter cohort study from the Korean Gynecologic Oncology Group Study (KGOG 1048).” Gynecologic oncology (2026). PMID: 42013607 ↗

    L3COHORTCited in: Outcomes
  179. [179]

    Ventriglia J, Paciolla I, Pisano C et al.. “Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.” Cancer treatment reviews (2017). PMID: 28800469 ↗

    L5REVIEW_NARRATIVECited in: Outcomes
  180. [180]

    Tu H, Huang H, Li Y et al.. “Sentinel-Lymph-Node Biopsy Alone or with Lymphadenectomy in Cervical Cancer.” The New England journal of medicine (2025). PMID: 41092328 ↗

    L1OTHERCited in: Outcomes
  181. [181]

    Kim SS, Shen S, Miyauchi S et al.. “B Cells Improve Overall Survival in HPV-Associated Squamous Cell Carcinomas and Are Activated by Radiation and PD-1 Blockade.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32193227 ↗

    L2OTHERCited in: Outcomes
  182. [182]

    Da Silva DM, Enserro DM, Mayadev JS et al.. “Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32816895 ↗

    L4OTHERCited in: Outcomes

Revision History

All updates applied to this page

Loading revisions…